Bttr. · Field Guide
What Is Biotech Software Development?
The design and engineering of software for biotechnology companies operating inside FDA, HIPAA, and GxP regulatory environments. Five surface categories, the constraints that shape them, and how biotech software differs from regular SaaS.
The short answer
Software for companies where the regulatory record is the product.
Biotech software development is the design and engineering of software for biotechnology companies. The work spans the lab bench to the patient app to the commercial platform, all operating inside regulatory environments that consumer SaaS never has to think about.
FDA 21 CFR Part 11. HIPAA. GxP (Good Manufacturing/Laboratory/ Clinical Practice). Validation. Traceability. Audit. The vocabulary biotech engineers live in does not show up in a regular SaaS roadmap. But it shapes every decision — schema design, deploy pipeline, even how you write commit messages.
The result is software that ships slower, costs more, and holds up longer. Year five matters. Launch screenshots do not.
The five surface categories
What biotech software actually is.
01
Lab-adjacent platforms
Software that runs next to actual lab work. Sample tracking, assay management, instrument integration, audit-traced data capture. The software the science team uses every day.
02
Clinical surfaces
EDC, ePRO, eConsent, clinical trial management. The software that touches patients, investigators, and the regulatory record. GxP-validated from week one.
03
Patient-facing biotech apps
Direct-to-patient surfaces — onboarding, scheduling, symptom tracking, treatment adherence. HIPAA-bound, often touching protected health information.
04
Commercial systems
B2B provider platforms, loyalty surfaces, brand sites, and the commercial UX that biotech companies ship to physicians, pharmacies, and patients post-approval.
05
Operations and BI
Internal dashboards, supply chain visibility, manufacturing telemetry, compliance reporting. The unglamorous backbone software biotech runs on.
What makes biotech software different
Five constraints that shape every decision.
Regulatory by default.
FDA 21 CFR Part 11, HIPAA, GxP (GMP/GLP/GCP), GDPR for international, and state-specific rules. Compliance is the brief, not a hardening pass after launch.
Validation as a development discipline.
Computer System Validation (CSV) means every change has IQ/OQ/PQ documentation. Test plans, traceability matrices, change controls. The software has to pass audit.
Long timelines, slow ROI.
Biotech software ships into multi-year clinical programs and decade-long commercial lifecycles. Year five matters. Launch screenshots do not.
High-stakes failure modes.
A bug in consumer SaaS is annoying. A bug in clinical software can affect patient safety or trial integrity. Engineering judgment has to account for that.
Senior team, no juniors.
Biotech software requires senior engineers who have shipped inside regulated environments before. Companies that staff juniors at validated layers end up rewriting.
Frequently asked
Biotech software development, common questions.
What is biotech software development?
Biotech software development is the design and engineering of software for biotechnology companies operating inside FDA, HIPAA, and GxP regulatory environments. The software spans lab-adjacent platforms, clinical surfaces (EDC/ePRO/eConsent), patient-facing apps, commercial systems, and internal operations. Unlike consumer SaaS, biotech software has to pass audit, support multi-year regulatory programs, and account for high-stakes failure modes.
What does biotech software actually do?
Biotech software covers five primary surface categories: lab-adjacent platforms (sample tracking, assay management), clinical surfaces (EDC, ePRO, eConsent, CTMS), patient-facing apps (onboarding, adherence, symptom tracking), commercial systems (provider platforms, loyalty, brand sites), and operations (manufacturing telemetry, compliance reporting). Most biotech companies ship some or all of these surfaces, each with its own regulatory and engineering constraints.
What makes biotech software different from regular SaaS?
Five things. (1) Regulatory by default — FDA, HIPAA, GxP, GDPR scoped into the system from week one. (2) Validation as a development discipline — CSV, IQ/OQ/PQ, traceability matrices. (3) Long timelines — software ships into multi-year clinical programs and decade-long commercial lifecycles. (4) High-stakes failure modes — bugs can affect patient safety or trial integrity. (5) Senior-only team requirements — juniors at validated layers end up rewriting.
Who builds biotech software?
Three options. Internal biotech engineering teams (most common at large pharma). Specialist biotech software vendors (Veeva, Medidata, Calyx, etc.). Senior product design and engineering agencies that work inside regulated environments (Bttr. is one). Choice depends on whether the surface is core to the company or commodity, and whether the company has senior in-house talent.
How long does biotech software development take?
Depends on the surface and the regulatory scope. A patient-facing onboarding flow: 6-12 weeks. A clinical EDC system: 6-18 months. A validated GxP commercial platform: 12-24 months. Validation timelines often double the build estimate. Biotech software development is slower than consumer SaaS for real reasons.
What is the role of design in biotech software?
Central. Biotech software has to be usable by clinicians, patients, lab scientists, and pharma operators — all under regulatory constraints. Good design reduces validation burden (fewer error states means fewer test cases), improves audit readiness (clear UX is auditable UX), and shortens time-to-trust (biotech buyers evaluate UX as a signal of operational maturity).
How much does biotech software development cost?
A patient-facing surface from a senior agency: $150-500K. A full clinical platform: $1-10M+. A validated commercial system: $500K-5M. Cost is driven primarily by regulatory scope (FDA submission-grade software is multiples more than non-submission software) and team seniority (senior-only teams cost more but rewrite less).
Does biotech software development require GxP validation?
Depends on what the software does. If it touches the regulatory record (clinical trial data, manufacturing records, GMP-relevant decisions), yes — full Computer System Validation (CSV) under 21 CFR Part 11. If it is commercial or patient-engagement surfaces, often no full CSV but still HIPAA and security validation. Scope this carefully at project start.
How does Bttr. approach biotech software development?
Senior product design and engineering team, regulatory constraints scoped from week one, validation discipline embedded in the engineering loop, and ongoing operate phase after launch. Bttr. has shipped biotech software for Tiger BioSciences and Allergan Aesthetics. Engagements typically begin with a discovery phase that maps regulatory scope, then move into design, build, and operate.